摘要:
Recombinant pre-S-HBsAg is purified by a rapid and efficient two step chromatographic process. Yeast cells expressing recobinant pre-S-HBsAg are disrupted, the cell contents are clarified and separated by polymerized human serum albumin affinity chromatography. The pre-S-HBsAg is further purified by hydrophobic interaction chromatography using butyl agarose. This process results in pre-S-HBsAg that is greater than 90% pure.
摘要:
Hepatitis B surface antigen (HBsAg) is produced in vitro in high titer and purity from tissue cultures of cells that shed HBsAg. The cells are grown on hollow fiber capillary units having a molecular weight cut-off of about 10,000.
摘要:
Hepatitis B surface antigen (HB.sub.s Ag) is produced in vitro in high titer and purity from tissue cultures of cells that shed HB.sub.s Ag by growing the cells with a first incubation at elevated temperature followed by a second incubation at a lower elevated temperature.
摘要:
Hepatitis B surface antigen free of gradient-derived added cesium and potassium ions, for example the antigen in an aqueous solution of sodium bromide.
摘要:
A multiplate propagator for producing cells and vaccines having critical geometric properties such as ratio of plate diameter to internal tank diameter results in significantly increased yields at substantially reduced costs.
摘要:
Semi-automated assays for viral infectivity and an assay for serum neutralizing antibody content are based on staining the cells and macroscopic reading of the cytopathic effect.
摘要:
Lyophilization time of live viral compositions is reduced and output per lyophilization unit is increased by lyophilizing a reduced volume of a more concentrated viral composition.
摘要:
Biological fluid containing hepatitis B surface antigen is subjected to isopycnic banding with collection of fractions rich in Dane particles. The Dane particles are useful as diagnostic and immunologic agents.
摘要:
Production of cells and vaccines utilizing a multiplate propagator in which the fluid dynamics of the system can be controlled during the growth cycle and/or the harvesting conditions can be controlled by rapidly cooling the harvested vaccine or by using multiple harvests, with or without automated collection of the vaccine thereby producing cells and vaccines in significantly increased yields and at substantially reduced costs in comparison with presently utilized procedures.